BR9712424A - Composição farmacêutica antagonista deneurotrofina - Google Patents
Composição farmacêutica antagonista deneurotrofinaInfo
- Publication number
- BR9712424A BR9712424A BR9712424-9A BR9712424A BR9712424A BR 9712424 A BR9712424 A BR 9712424A BR 9712424 A BR9712424 A BR 9712424A BR 9712424 A BR9712424 A BR 9712424A
- Authority
- BR
- Brazil
- Prior art keywords
- lower alkyl
- pharmaceutical composition
- alkyl
- optionally substituted
- neurotrophin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
| GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
| PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9712424A true BR9712424A (pt) | 2001-11-20 |
Family
ID=26310264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9712424-9A BR9712424A (pt) | 1996-10-21 | 1997-10-20 | Composição farmacêutica antagonista deneurotrofina |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20020169182A1 (https=) |
| EP (1) | EP0930883B1 (https=) |
| JP (1) | JP2001503397A (https=) |
| KR (1) | KR20000052691A (https=) |
| AT (1) | ATE315397T1 (https=) |
| AU (1) | AU728523C (https=) |
| BR (1) | BR9712424A (https=) |
| CA (1) | CA2268450C (https=) |
| DE (1) | DE69735090T2 (https=) |
| DK (1) | DK0930883T3 (https=) |
| ES (1) | ES2257768T3 (https=) |
| IL (1) | IL129475A0 (https=) |
| NZ (1) | NZ335291A (https=) |
| WO (1) | WO1998017278A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0930883B1 (en) | 1996-10-21 | 2006-01-11 | Allelix Biopharmaceuticals Inc. | Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain |
| MXPA01005228A (es) * | 1998-11-25 | 2002-06-21 | Merck Patent Gmbh | Benzo(de)isoquinolin-1, 3-dionas substituidas. |
| AU760136B2 (en) * | 1998-11-25 | 2003-05-08 | Merck Patent Gmbh | Substituted benzo(DE)isoquinoline-1,3-diones |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| EP2191846A1 (en) | 2003-02-19 | 2010-06-02 | Rinat Neuroscience Corp. | Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| JP5301152B2 (ja) | 2004-04-07 | 2013-09-25 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法 |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| BRPI0615930A2 (pt) * | 2005-09-15 | 2016-08-23 | Painceptor Pharma Corp | métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo, e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| JP2021517461A (ja) | 2018-03-12 | 2021-07-26 | ゾエティス・サービシーズ・エルエルシー | 抗ｎｇｆ抗体およびその方法 |
| CA3190144A1 (en) * | 2020-07-24 | 2022-01-27 | Jawaharlal Nehru Centre For Advanced Scientific Research | Naphthalene monoimide compounds and methods thereof |
| US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
| AU2024238259A1 (en) | 2023-03-17 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for osteoarthritis (oa) |
| WO2026054762A1 (en) | 2024-09-05 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for adjudicated arthropathy (aa) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US525841A (en) * | 1894-09-11 | Baling-press | ||
| US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
| US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
| US4006238A (en) * | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
| ES459497A1 (es) * | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
| US5183821A (en) * | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
| DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| DE3707651A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
| US5420137A (en) * | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| CA2030129A1 (en) * | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
| US5342942A (en) * | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
| DE4232739A1 (de) * | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
| IL110460A (en) * | 1993-08-18 | 2001-01-11 | Basf Ag | Bis-naphthalimides, their preparation and pharmaceutical compositions containing them |
| US6291247B1 (en) * | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| GB9616105D0 (en) * | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
| EP0930883B1 (en) | 1996-10-21 | 2006-01-11 | Allelix Biopharmaceuticals Inc. | Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain |
| CA2319680C (en) | 1997-02-07 | 2010-04-20 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO1998052919A1 (en) | 1997-05-21 | 1998-11-26 | Japan Tobacco Inc. | Phthalimide derivatives and pharmaceutical containing said derivatives |
| WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
| EP1020446B1 (en) * | 1998-07-03 | 2006-03-15 | Taiho Pharmaceutical Co., Ltd. | Naphthalimidobenzamide derivatives |
| US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
-
1997
- 1997-10-20 EP EP97909098A patent/EP0930883B1/en not_active Expired - Lifetime
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en not_active Ceased
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Withdrawn
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7291629B2 (en) | 2007-11-06 |
| IL129475A0 (en) | 2000-02-29 |
| AU4696897A (en) | 1998-05-15 |
| AU728523B2 (en) | 2001-01-11 |
| ES2257768T3 (es) | 2006-08-01 |
| WO1998017278A1 (en) | 1998-04-30 |
| ATE315397T1 (de) | 2006-02-15 |
| DK0930883T3 (da) | 2006-05-22 |
| US20080287484A1 (en) | 2008-11-20 |
| DE69735090D1 (de) | 2006-04-06 |
| US20050250807A1 (en) | 2005-11-10 |
| DE69735090T2 (de) | 2006-09-14 |
| EP0930883B1 (en) | 2006-01-11 |
| CA2268450A1 (en) | 1998-04-30 |
| CA2268450C (en) | 2008-08-05 |
| AU728523C (en) | 2001-08-09 |
| KR20000052691A (ko) | 2000-08-25 |
| US20020169182A1 (en) | 2002-11-14 |
| EP0930883A1 (en) | 1999-07-28 |
| JP2001503397A (ja) | 2001-03-13 |
| US20090215815A1 (en) | 2009-08-27 |
| NZ335291A (en) | 2001-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9712424A (pt) | Composição farmacêutica antagonista deneurotrofina | |
| IT1314184B1 (it) | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo | |
| ATE277066T1 (de) | Bicyclonucleosid-analoga | |
| CA2280850A1 (en) | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies | |
| IL144826A0 (en) | Amide compounds and pharmaceutical compositions containing the same | |
| NO20003018L (no) | Triazinangiogenese-inhibitorer | |
| UA41875C2 (uk) | Спосіб інгібування естрогензалежних пухлин з використанням стероїдних сульфатовмісних інгібіторів | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| ATE292628T1 (de) | Chinazolinderivate | |
| SE9203825L (sv) | Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma | |
| ATE287715T1 (de) | Verwendung von oxidosqualencyclasehemmer zur senkung des cholesterinblutspiegels | |
| CY1108367T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| NO991494D0 (no) | <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer | |
| IL175398A0 (en) | Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation | |
| CA2250861A1 (en) | Cyclic adhesion inhibitors | |
| PL341050A1 (en) | Heterocyclic cytoxic agents | |
| IL136359A (en) | Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same | |
| PE20011318A1 (es) | Compuestos fenilo sustituidos inhibidores de la farnesiltransferasa | |
| ES2093091T3 (es) | Derivado de glutation. | |
| MXPA05003909A (es) | Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer. | |
| BR0307266A (pt) | Compostos que inibem a atividade do fator xa | |
| BR0209776A (pt) | Composições de inibidores seletivos de ciclo oxigenase-2 e radiação para inibição ou prevenção de doença cardiovascular | |
| DK0660840T3 (da) | Phosphono-substituerede tetrazolderivater. | |
| NO20014268D0 (no) | Syrekatalyserte reaksjoner | |
| TW200514778A (en) | Haloalkyl-and piperidine-substituted benzimidazole-derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |